Featured Research

from universities, journals, and other organizations

Scientists revisit 'Hallmarks of Cancer'

Date:
March 16, 2011
Source:
Whitehead Institute for Biomedical Research
Summary:
Cancer researchers have updated the "Hallmarks of Cancer," a seminal review that codified the traits that all cancers have in common. The original article has influenced scientists, both in and outside cancer research. The revised work incorporates information gleaned from the past eleven years of cancer research and is expected to have a strong impact on the study of cancer and the quest for approaches to treat it.

Cancer researchers Robert Weinberg, a Founding Member of Whitehead Institute, and Douglas Hanahan, Director of the Swiss Institute for Experimental Cancer Research (ISREC) have updated their seminal review, "Hallmarks of Cancer," which has influenced the study of cancer and the development of therapeutics for more than a decade.

Published in January 2000, their original work, which codified the traits that all cancers have in common, would go on to become the most-cited article ever to appear in the journal Cell. Their new paper, "Hallmarks of Cancer: The Next Generation," incorporates information gleaned from the past eleven years of cancer research. This latest review, found in a recent edition of Cell, is expected to have a similarly strong impact on the study of cancer and the quest for approaches to treat it.

Cancer is a large class of very different diseases, all of which grow uncontrollably and have the ability to spread, or metastasize, throughout the body. Thousands of studies annually try to decipher these diseases and produce immense datasets that are not necessarily applicable across the constellation of cancers. To help researchers develop a functional framework for cancer as a whole, the first article distilled all of the existing research to describe six fundamental characteristics of cancer.

"The six organizing principles we proposed in the year 2000 have found, I would say, rather wide acceptance," says Weinberg, who is also a professor of biology at Massachusetts Institute of Technology. "Having gone back and critically examined them, we were most reassured that they still seemed to be robust; we had converged on fundamental principles that to this day seem to be essential to the process of creating cancer."

The original six hallmarks are: self-sufficiency in growth signals, insensitivity to anti-growth signals, tissue invasion and metastasis, limitless replicative potential, sustained angiogenesis (blood vessel growth), and evasion of apoptosis (cell death). In the updated version, the authors refined these hallmarks using information from transgenic animals and biochemical assays that did not exist a decade ago.

Hanahan and Weinberg also added two categories in the update: "enabling characteristics" and "emerging hallmarks.." The two enabling characteristics of cancer-- tumor-promoting inflammation and gene instability and mutation--do not necessarily cause cancer but assist cells in a transition from normal to oncogenic.

Although common characteristics of many cancers, the two emerging hallmarks (reprogramming of energy metabolism and evasion of the immune system) have not been integrated into the canonical six because Hanahan and Weinberg remain unsure whether they are pervasive in all cancers.

In addition to providing a solid basis for cancer research, the hallmarks have served to identify certain cell functions that have become therapeutic targets. However, the utility of such attempts has been limited because tumor cells have demonstrated an ability to develop resistance to drugs that disrupt a single pathway. This adaptability of cancer cells suggests to Hanahan and Weinberg that simultaneous targeting of two or more hallmark pathways may be a more effective approach to therapy.


Story Source:

The above story is based on materials provided by Whitehead Institute for Biomedical Research. The original article was written by Nicole Giese. Note: Materials may be edited for content and length.


Journal Reference:

  1. Douglas Hanahan, RobertA. Weinberg. Hallmarks of Cancer: The Next Generation. Cell, 2011; 144 (5): 646 DOI: 10.1016/j.cell.2011.02.013

Cite This Page:

Whitehead Institute for Biomedical Research. "Scientists revisit 'Hallmarks of Cancer'." ScienceDaily. ScienceDaily, 16 March 2011. <www.sciencedaily.com/releases/2011/03/110316113057.htm>.
Whitehead Institute for Biomedical Research. (2011, March 16). Scientists revisit 'Hallmarks of Cancer'. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2011/03/110316113057.htm
Whitehead Institute for Biomedical Research. "Scientists revisit 'Hallmarks of Cancer'." ScienceDaily. www.sciencedaily.com/releases/2011/03/110316113057.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins